Clearly, not every prostate cancer patient will benefit from novel endocrine treatments, Gary Culliton reports in his latest Clinical Update. Thus, personalised medicine is key. The challenge now is to identify which patients will benefit from the drugs and which will not.
Researchers at Trinity College Dublin and Mount Sinai in New York have published new research, which for the first time provides strong evidence on the economic benefits of early palliative care intervention for people with an advanced cancer diagnosis.
Men with a high fitness level in mid-life appear to be at lower risk for lung and colorectal cancer, but not prostate cancer, and that higher fitness level also may put them at lower risk of death if they are diagnosed with cancer when they’re older, according to a study published online by JAMA Oncology.
Breast cancer survival has improved as a result of screening, symptomatic detection and better treatment options, Gary Culliton reports in his latest Clinical Update. The volume of care now being delivered at cancer centres is substantial.
In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in improved survival and had a favourable risk-benefit profile, new research in the New England Journal of Medicine has found.
Higher proportions of women eligible for breast conservation surgery (BCS) are undergoing mastectomy, breast reconstruction and bilateral mastectomy, with large increases seen in women with lymph node-negative and in situ disease, according to a report published online by JAMA Surgery.
The cure rates for early-stage colon and rectal cancers can be over 90 per cent. In Europe and the US these are among the most common of cancers.
Within the next 10 to 15 years, three-quarters of patients with colorectal cancer can be expected to survive five years or longer – a huge jump in a relatively short period, Gary Culliton reports in his latest Clinical Update.
Patients have a range of options available to them before and following chemotherapy, a meeting of European experts has heard. Michelle McDonagh reports.
Endocrine treatments are directed at patients who express the oestrogen receptor. In around 75 percent of breast cancers, oestrogen encourages them to grow. This type of breast cancer can be treated with drugs such as tamoxifen but many people develop resistance and see their breast cancer return.